| First Author | Post J | Year | 2021 |
| Journal | Int J Mol Sci | Volume | 22 |
| Issue | 13 | PubMed ID | 34209129 |
| Mgi Jnum | J:357587 | Mgi Id | MGI:6751148 |
| Doi | 10.3390/ijms22137066 | Citation | Post J, et al. (2021) Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1(G93A) Transgenic Mice. Int J Mol Sci 22(13) |
| abstractText | Neuroinflammation is a pathological hallmark of several neurodegenerative disorders and plays a key role in the pathogenesis of amyotrophic lateral sclerosis (ALS). It has been implicated as driver of disease progression and is observed in ALS patients, as well as in the transgenic SOD1(G93A) mouse model. Here, we explore and validate the therapeutic potential of the d-enantiomeric peptide RD2RD2 upon oral administration in SOD1(G93A) mice. Transgenic mice were treated daily with RD2RD2 or placebo for 10 weeks and phenotype progression was followed with several behavioural tests. At the end of the study, plasma cytokine levels and glia cell markers in brain and spinal cord were analysed. Treatment resulted in a significantly increased performance in behavioural and motor coordination tests and a decelerated neurodegenerative phenotype in RD2RD2-treated SOD1(G93A) mice. Additionally, we observed retardation of the average disease onset. Treatment of SOD1(G93A) mice led to significant reduction in glial cell activation and a rescue of neurons. Analysis of plasma revealed normalisation of several cytokines in samples of RD2RD2-treated SOD1(G93A) mice towards the levels of non-transgenic mice. In conclusion, these findings qualify RD2RD2 to be considered for further development and testing towards a disease modifying ALS treatment. |
